182 related articles for article (PubMed ID: 37729414)
1. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia.
Robinson TM; Bowman RL; Persaud S; Liu Y; Neigenfind R; Gao Q; Zhang J; Sun X; Miles LA; Cai SF; Sciambi A; Llanso A; Famulare C; Goldberg A; Dogan A; Roshal M; Levine RL; Xiao W
Sci Adv; 2023 Sep; 9(38):eadg0488. PubMed ID: 37729414
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
Zeijlemaker W; Kelder A; Cloos J; Schuurhuis GJ
Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
[TBL] [Abstract][Full Text] [Related]
3. Improved detection of measurable residual disease in acute myeloid leukemia.
Zhang X; Grimes HL
Sci Adv; 2023 Sep; 9(38):eadk2533. PubMed ID: 37729410
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
Brooimans RA; van der Velden VHJ; Boeckx N; Slomp J; Preijers F; Te Marvelde JG; Van NM; Heijs A; Huys E; van der Holt B; de Greef GE; Kelder A; Schuurhuis GJ
Leuk Res; 2019 Jan; 76():39-47. PubMed ID: 30553189
[TBL] [Abstract][Full Text] [Related]
5. Single-cell mutational profiling enhances the clinical evaluation of AML MRD.
Ediriwickrema A; Aleshin A; Reiter JG; Corces MR; Köhnke T; Stafford M; Liedtke M; Medeiros BC; Majeti R
Blood Adv; 2020 Mar; 4(5):943-952. PubMed ID: 32150611
[TBL] [Abstract][Full Text] [Related]
6. Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them.
Li SQ; Chen M; Huang XY; Wang H; Chang YJ
Expert Rev Hematol; 2023; 16(12):981-990. PubMed ID: 37978882
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
8. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia exhibiting clonal instability during treatment: Implications for measurable residual disease assessments.
Simonsen AT; Meggendorfer M; Hansen MH; Nederby L; Koch S; Hansen M; Rosenberg CA; Kern W; Nyvold CG; Aggerholm A; Haferlach T; Ommen HB
Exp Hematol; 2022 Mar; 107():51-59. PubMed ID: 35122908
[TBL] [Abstract][Full Text] [Related]
10. A 19-color single-tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia.
Fokken H; Waclawski J; Kattre N; Kloos A; Müller S; Ettinger M; Kacprowski T; Heuser M; Maetzig T; Schwarzer A
Cytometry A; 2024 Mar; 105(3):181-195. PubMed ID: 37984809
[TBL] [Abstract][Full Text] [Related]
11. Should minimal residual disease guide therapy in AML?
Paietta E
Best Pract Res Clin Haematol; 2015; 28(2-3):98-105. PubMed ID: 26590765
[TBL] [Abstract][Full Text] [Related]
12. Progress of minimal residual disease studies in childhood acute leukemia.
Campana D
Curr Hematol Malig Rep; 2010 Jul; 5(3):169-76. PubMed ID: 20467922
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease in acute myeloid leukemia: coming of age.
Paietta E
Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558
[TBL] [Abstract][Full Text] [Related]
14. Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.
Ganzel C; Sun Z; Baslan T; Zhang Y; Gönen M; Abdel-Wahab OI; Racevskis J; Garrett-Bakelman F; Lowe SW; Fernandez HF; Ketterling R; Luger SM; Litzow M; Lazarus HM; Rowe JM; Tallman MS; Levine RL; Paietta E
Leuk Res; 2022 Dec; 123():106971. PubMed ID: 36332294
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Aitken MJL; Ravandi F; Patel KP; Short NJ
J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626
[TBL] [Abstract][Full Text] [Related]
16. The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease.
Hsu FC; Hudson C; Wilson ER; Pardo LM; Singleton TP; Xu D; Zehentner BK; Hitzler J; Berman J; Wells DA; Loken MR; Brodersen LE
Cytometry B Clin Cytom; 2023 Jul; 104(4):311-318. PubMed ID: 37015883
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
[TBL] [Abstract][Full Text] [Related]
18. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.
van der Velden VH; van der Sluijs-Geling A; Gibson BE; te Marvelde JG; Hoogeveen PG; Hop WC; Wheatley K; Bierings MB; Schuurhuis GJ; de Graaf SS; van Wering ER; van Dongen JJ
Leukemia; 2010 Sep; 24(9):1599-606. PubMed ID: 20668473
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
San Miguel JF; Martínez A; Macedo A; Vidriales MB; López-Berges C; González M; Caballero D; García-Marcos MA; Ramos F; Fernández-Calvo J; Calmuntia MJ; Diaz-Mediavilla J; Orfao A
Blood; 1997 Sep; 90(6):2465-70. PubMed ID: 9310499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]